Guides · Sponsors

Ethics review for a company-run pet study

No federal rule names a reviewer for a company-run pet study; use the site's board or a committee you convene, and show it the protocol and consent form.

Published November 5, 2026 · sources checked November 5, 2026. Signalment is a data system; the protocol, the ethics review, the consent and any filing stay with the sponsor and the investigators.

No federal rule says who must review a company-run study in client-owned pets. 21 CFR 511.1, the rule for investigational animal drugs, names no ethics committee, and a company that neither buys nor transports the animals and takes no federal research money is not a research facility under the Animal Welfare Act, the status that brings an IACUC. Review still happens, because teaching hospitals and journals ask for it and good clinical practice asks the sponsor to weigh animal welfare first. The reviewer is the site's own board when the study runs at a veterinary school, or a committee the sponsor convenes or contracts on the IACUC pattern: at least three people, one a veterinarian and one with no tie to the company. They need to see the protocol, the owner consent form and everything else owners will read, the safety plan, and the status of the product.

Is a committee required?

21 CFR 511.1(b) lets a new animal drug ship for clinical investigation once its conditions are met: investigational labelling, a "Notice of Claimed Investigational Exemption for a New Animal Drug" filed before shipment (b)(4), complete records (b)(7), and monitoring and hazard reports by the sponsor (b)(8). It mentions no IACUC, ethics committee or owner consent.

The IACUC comes from the Animal Welfare Act. Under 9 CFR 1.1, a research facility uses live animals in research "and that (1) purchases or transports live animals in commerce, or (2)" receives federal research funds. Only a research facility must keep a committee under 9 CFR 2.31. A sponsor whose study animals stay with their owners and their own veterinarians usually meets neither condition, and the instructions to APHIS Form 7023, USDA's annual report for research facilities, say "DO NOT include animals used in clinical trials in the context of a Veterinary- Client relationship." A federal grant changes the answer. Have counsel confirm your own facts.

Guidance #85 (VICH GL9), FDA's good clinical practice standard, names no committee either. It asks investigator (3.2.12) and sponsor (4.2.17) to comply with "applicable regulatory requirements governing the humane care of study animals", and the sponsor to determine that there are "no environmental, animal welfare, or scientific grounds which might preclude the conduct of a clinical study" (4.2.1). CVM's draft Guidance #282 (September 2023, not final) notes "there are no Federal laws that regulate the informed consent process" for investigational drug studies in client-owned companion animals (V.A), yet recommends a consent form for every study with client-owned dogs, cats or horses (I). An outside review puts that 4.2.1 judgment on record.

Who can review the study?

  1. The site's board. At a veterinary teaching hospital the choice is made for you. UC Davis's Clinical Trial Review Board advises the IACUC and "will pre-review all protocols involving VMTH patients", and a clinical trial's protocol must "include an attached owner informed Consent Form." Texas A&M's Clinical Research Review Committee reviews a study when "non-residual sample collection, diagnostics, treatment, or animal care is influenced by considerations other than the needs of the patient", and asks for the animal use protocol and consent form five weeks before its meeting.
  2. A committee you convene. Borrow 9 CFR 2.31(b): a chair and at least two more members, at least one a veterinarian, and at least one "not affiliated in any way with the facility". For a sponsor, that is a veterinarian outside the study team and a member from outside the company. Write down how a member with a stake in the result steps aside, and keep minutes and a signed approval letter.
  3. A committee you contract. An independent animal ethics committee, or another institution's IACUC that takes outside protocols. Ask for its membership, its conflict policy and how it handles amendments and adverse events after approval.

For a study meant for FDA, GL9 6.2 encourages the regulator's review of the protocol before the study starts, and draft #282 section VII asks a sponsor seeking concurrence on its consent form to submit it with the protocol. A journal may ask at the end: Frontiers' policy asks authors to "confirm that written informed consent has been granted by the owner(s)", and wants research with regulated animals "reviewed and approved by an ethics committee prior to commencing the study".

What reviewers need to see

What to sendWhat it should showFrom
The protocol, signed and dated by sponsor and investigator, with its number, status and version dateObjective, design, randomization and blinding, inclusion, exclusion and removal criteria, doses and why, endpoints, statistics and sample sizeGL9 1.29, 6.3
A description of the animal useSpecies and approximate number, why animals and why that number, each procedure, how pain and distress are kept to what is unavoidable, any euthanasia method9 CFR 2.31(e)
The owner consent formThat the study's purpose is not treatment; the groups and the chance of control; alternatives; owner duties and costs; procedures outside usual care; risks; withdrawal without penalty; confidentiality, including that FDA may inspect; contactsDraft #282 VI
Everything else owners readRecruitment text, visit schedule, diary instructionsGL9 6.3.20.3
The safety planHow often animals are checked, what is done on an adverse event (including breaking the blind), how it is recorded and reported, care for animals removed from the studyGL9 6.3.19, 6.3.15.2
The product's statusApproved and used as labelled, or unapproved with the 511.1 notice filed21 CFR 511.1(b)(4)

An IACUC-style committee then applies 9 CFR 2.31(d)(1): procedures that "avoid or minimize discomfort, distress, and pain", pain relief for painful procedures, and medical care from a qualified veterinarian.

How does the design change the answer?

What stays with the sponsor and the investigator?

They write the protocol, choose the reviewer and answer its questions, keep the approval letter and its conditions, write the consent content, file the 511.1 notice where it applies, and report adverse events and hazards. Send each protocol amendment back to the reviewer before it takes effect. GL9 4.3.1 keeps "ultimate responsibility for the quality and integrity of the study data" with the sponsor. A data system cannot approve a study or decide what owners are told.

Where Signalment fits

Signalment is a data system for running the study once it is approved. Protocol and consent are versioned, and owners can sign consent on their own phone, each signature bound to the exact version of the text they read, so a reviewer can match signatures to the approved version. Team signatures re-check the signer's password, changes go on an append-only, hash-chained audit trail, and the workspace carries a compliance guide covering INAD, IACUC, VICH GL9 and 21 CFR Part 11. It does not review or approve studies, keep a committee or write consent content, and drug accountability ledgers are not built yet. The sponsor's view is at signalment.app/sponsors; for the form itself, see Informed consent for client-owned animal studies.

Sources

Your next study

See it with your own study.

A 20-minute demo: an example study across four clinics, then how yours would be set up. Or start from a template in a free workspace.